0QNV Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.10 |
| 52 Week High | CHF0.19 |
| 52 Week Low | CHF0.055 |
| Beta | 1.76 |
| 1 Month Change | 21.49% |
| 3 Month Change | 37.09% |
| 1 Year Change | n/a |
| 3 Year Change | -93.10% |
| 5 Year Change | -94.16% |
| Change since IPO | -94.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QNV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -43.7% | 2.1% | 1.4% |
| 1Y | n/a | -27.7% | 1.1% |
Return vs Industry: Insufficient data to determine how 0QNV performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0QNV performed against the UK Market.
Price Volatility
| 0QNV volatility | |
|---|---|
| 0QNV Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QNV's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0QNV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| 0QNV fundamental statistics | |
|---|---|
| Market cap | CHF14.81m |
| Earnings (TTM) | -CHF10.56m |
| Revenue (TTM) | CHF1.65m |
9.0x
P/S Ratio-1.4x
P/E RatioIs 0QNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QNV income statement (TTM) | |
|---|---|
| Revenue | CHF1.65m |
| Cost of Revenue | CHF6.94m |
| Gross Profit | -CHF5.29m |
| Other Expenses | CHF5.27m |
| Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | -0.082 |
| Gross Margin | -321.08% |
| Net Profit Margin | -640.91% |
| Debt/Equity Ratio | 0% |
How did 0QNV perform over the long term?
See historical performance and comparison